Europe

#Antimicrobial resistance (AMR) #Cell and gene therapy #Europe #Immunology / Virology & Vaccines #Market reporting #mRNA #Plant-based

Read the Spring issue of DDW now

The Spring issue of Drug Discovery World (DDW) is out now. It looks at where we are in the fight against antimicrobial resistance, explores how structural biology is informing vaccine design, and offers advice on approaching dealmaking in biopharma. Read the digital version here. … Read More

#News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

The European Medicines Agency building
#EFPIA #Europe #Orphan drugs #Pharmaceuticals #Rare disease #Regulatory

Proposed changes to EU regulation risks progress on orphan drugs

Plans to overhaul the EU regulation on rare disease therapies risk undermining two decades of progress, a new report claims. The assessment, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), was conducted by Dolon, a strategic consultancy specialising in rare diseases. The European Orphan Medicinal Product Regulation… Read More

#News #Regulatory

Patient receiving vaccine
#Covid-19 #EU #Europe #Immunology / Virology & Vaccines #Vaccines

EU’s position as vaccines leader “at risk”, report reveals

The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE). The EU has hosted approximately 20% of global vaccine clinical trials over the past two decades, as well as research… Read More

#News #Trends & Analysis

Job hire
#Appointment #Drug development #Europe

Norgine appoints new COO to drive European position  

Specialist pharmaceutical company Norgine has appointed Saulo Martiniano as its new Chief Operating Officer (COO).  Martiniano previously worked at L’Oréal and was responsible for leading Global Manufacturing Excellence across 38 plants that included more than 10,000 employees.  Martiniano will now be based in the UK and… Read More

#News

EU flag
#Brexit #Europe #Funding #Horizon Europe #Life sciences #UK government

Horizon Europe delay damaging UK’s reputation as a science leader

As negotiations continue between the UK and EU over Horizon Europe, the largest collaborative research programme in the world, the scientific research community has urged the Prime Minister to secure the UK’s membership as soon as possible.  Figures reported in The Guardian from the European… Read More

#News #Trending News

#Europe #Funding #Investment #Life sciences #Start-ups

European life sciences investor raises over €95 million

Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The company plans to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build a portfolio of 10-15… Read More

#Business & Investment #News #Start-up Zone

Pills
#EMA #Europe #Hypertension #Janssen #Phase III trial

Janssen seeks EMA approval for hypertension combination therapy

Janssen has submitted a marketing authorisation application to the European Medicines Agency (EMA) seeking approval of single tablet combination therapy (STCT) of macitentan and tadalafil for pulmonary arterial hypertension (PAH). The single tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) is intended for the long-term treatment of… Read More

#News #Regulatory

Research in genetics laboratory
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #Europe #Rare disease

Proposed EU clinical assessment rules would reject ATMPs

The proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorised in the EU, claims the Alliance for Regenerative Medicine (ARM). According to ARM, all seven gene therapies for rare genetic diseases would have been rejected under the baseline methodologies proposed… Read More

#Editor's Choice #News

Genomics
#Europe #Genetics / genomics #Genomics #Immunotherapy #Oncology #Personalised medicine #The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Coalition will promote access to genomic profiling in Europe

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP). It is hoped that the Coalition will improve cancer care through increased routine clinical access and… Read More

#News

Lottery
#EFPIA #Europe #Marketing approval authorisation #Regulatory

EFPIA report highlights Europe’s medicines lottery

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a series of reports about the availability of new medicines throughout Europe. EFPIA’s 2022 Patient WAIT Indicator tracks the availability of new medicines and length of time it takes patients to get them in 37 countries in the EU… Read More

#News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #Automation / robotics #Europe #Events #High throughput screening #Lab automation #SLAS Europe

What to expect from SLAS Europe 2023

SLAS Europe 2023 will take place 22-26 May in Brussels, Belgium, where attendees will embrace the theme Science Set in Motion. DDW’s Multimedia Editor Megan Thomas explores what to expect from the event. Scientific tracks SLAS Europe 2023 will feature four tracks focused on life sciences and their global impact:… Read More

#Exclusive Content

Woman bleeding from the nose
#CHMP #CSL #Europe #European Commission #Haemophilia #Marketing approval authorisation

EU-approved gene therapy reduced haemophilia bleeds by 64%

The European Commission has granted conditional marketing authorisation for CSL’s Hemgenix (etranacogene dezaparvovec), the first one-time gene therapy for severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.   In an ongoing clinical trial, the drug reduced the… Read More

#Editor's Choice #News

#AI #Antimicrobial resistance (AMR) #Bioscience #Drug development #Europe #Phage therapy #Research

Grant will allow development of phage therapy diagnostic platform 

Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, has received €1.8 million in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project.  The project is a phagogram using artificial intelligence (AI) that… Read More

#News

Myeloma cells
#Antibody #Cancer research #Europe #European Medicines Agency #Janssen #Marketing approval authorisation #Myeloma #T-Cells

Janssen seeks European approval for multiple myeloma drug

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More

#Cancer Research #News

Prostate-specific membrane antigen
#Cancer research #Europe #Novartis #Oncology #Prostate cancer

New prostate cancer drug approved in Europe

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen).   The drug was developed under the leadership of the German Cancer Research Center (DKFZ)… Read More

#Cancer Research #News #Trending News